Skip to main content
Premium Trial:

Request an Annual Quote

Genospectra, French CNRS to Co-Develop Delivery Reagents; Firm Exclusively Licenses Tech

NEW YORK, July 19 (GenomeWeb News) - Genospectra has licensed a technology to deliver reagents into cells from the French National Center for Scientific Research and will collaborate with CNRS to develop new delivery reagents, the company said today.


The agreement gives Fremont-Calif.-based Genospectra an exclusive worldwide license to the MPG technology, which was developed by researchers at the CNRS in Montpellier. The partners plan to co-develop a panel of delivery reagents optimized to transfer a wide variety of molecules into live cells, which Genospectra has the right to market and sell.


Genospectra and CNRS have been collaborating for two years, and Genospectra recently released its first delivery reagent based on the technology for transferring siRNA into cells.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.